Guan X, Wang L, Cao Y, Shi F, Xu H, Ding J, Wu M, Li H. A Erratum on Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China. Health Decision [Internet]. 2023 Nov. 24 [cited 2024 May 10];1. Available from: https://www.hksmp.com/journals/hd/article/view/498